US Pharma MarketingMadrigal Pharmaceuticals has licensed rights to an Arrowhead Pharmaceuticals small-interfering RNA therapy designed to address a particular genetic mutation associated with the fatty liver disease MASH. It’s Madrigal’s fourth business development deal of the past year and the company’s second one involving siRNA therapies. Toggle Search Close navigation News Health Tech BioPharma Devices & Diagnostics Consumer / Employer Contributors MedCity Influencers Events Bullseye INVEST Digital Health Podcasts Research Newsletters Newsletter Signup Send Tips Webinars eBooks Twitter Facebook TikTok YouTube LinkedIn RSS Subscribe via email Search for: Search BioPharma, Pharma Madrigal Pharma Adds Another Genetic Medicine to Its Drug Combo Strategy…
Madrigal Pharmaceuticals has licensed rights to an Arrowhead Pharmaceuticals small-interfering RNA therapy designed to address a particular genetic mutation associated with the fatty liver disease MASH. It’s Madrigal’s fourth business development deal of the past year and the company’s second one involving siRNA therapies.
The post Madrigal Pharma Adds Another Genetic Medicine to Its Drug Combo Strategy in MASH appeared first on MedCity News.
Source: MedCity News